Oracle Completes Acquisition of Phase Forward
Oracle and Phase Forward executives offered their welcome as Phase Forward officially becomes part of the Oracle Health Sciences Global Business Unit.
The Webex conference for customers and partners this morning allowed Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences, to provide Oracle's overarching strategy in regard to IT in all vertical markets. He then drilled down into its strategy for the Health Sciences unit, which is based on the ultimate convergence of life sciences and healthcare processes into translational and personalized medicine--and specifically using the efficiencies of data interoperability as necessary to achieve the goals.
From Phase Forward's perspective, both Steve Rosenberg, Senior Vice President, Products and Services, and Steve Powell, Senior Vice President Global Sales and Marketing, presented the benefits of the merger for customers. The main takeaway from Rosenberg for Phase Forward customers was that their "investment protected and their services intact."
In the new structure, customers will be able to take advantage of Oracle's Applications Unlimited, which offers customers basically whatever they choose moving forward..stay on the existing platform, upgrade or update to others, etc.
Powell reiterated that the merger was transformational in the industry and that by choosing Phase Forward, Oracle emphasizes the need of its applications within this industry, which will command a significant level of investment in the coming years.
Powell said that all upcoming Oracle and Phase Forward events this year are unaffected by the purchase. These events include Oracle's Open World, on September 19-23 in San Francisco, the Prix Galien on September 28 in New York City, Oracle Health Sciences User Group Annual Conference on October 10-13 in San Antonio, TX, and the Phase Forward International Users Conference in Orlando on October 26-28.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
